Economic Costs of Myasthenia Gravis: A Systematic Review.
Erik LandfeldtOksana PogoryelovaThomas SejersenNiklas ZethraeusAri BreinerHanns LochmüllerPublished in: PharmacoEconomics (2021)
We show that the current body of literature of costs of MG is sparse, limited to a few geographical settings and resource categories, mostly dated, and subject to non-trivial variability, both within and between countries. Our synthesis will help researchers and decision-makers identify gaps in the local health economic context of MG and inform future cost studies and economic evaluations in this patient population.